PTC THERAPEUTICS, INC. (PTCT) Form 10-Q — Oct 29, 2026
PTC Therapeutics reported Q3 2026 total revenue of $357.8 million, up 69.6% from $211.0 million a year earlier, driven by net product revenue more than doubling to $275.9 million on the Sephience PKU launch. The company swung to a quarterly net loss of $51.7 million ($(0.62) per share) versus net income of $15.9 million in Q3 2025, largely due to a $111.0 million acquired IPR&D charge for the September 2026 acquisition of Sangamo's ST-920 Fabry gene therapy plus a $19.3 million loss on extinguishment of its 2026 convertible notes.
Key figures
- Revenue
- 357807000
- Total Debt
- 536268000
- Revenue Yoy
- +69.6% (total Q3 revenue $357.8M vs $211.0M)
- Total Assets
- 3207715000
- Cash Position
- 508894000
- Shares Outstanding
- 83544284
- Sangamo upfront
- 111000000
- Nine month revenue
- 990877000
- Q3 2025 net income
- 15896000
- Q3 royalty revenue
- 81684000
- Marketable securities
- 1619024000
- Nine month net income
- 28994000
- Nine month diluted eps
- 0.34
- Q3 net product revenue
- 275894000
- Royalty liability total
- 2305603000
- 2031 notes conversion price
- 107.48
- Loss on debt extinguishment
- 19263000
- Sangamo contingent milestones
- 100000000
- 2031 convertible notes principal
- 550000000
- Royalty liability effective rate
- 11.0%
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.